These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15072437)

  • 21. Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR gamma crystal structure.
    Lewis DF; Jacobs MN; Dickins M; Lake BG
    Toxicol In Vitro; 2002 Jun; 16(3):275-80. PubMed ID: 12020601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods.
    Loiodice F; Pochetti G
    Curr Top Med Chem; 2011; 11(7):819-39. PubMed ID: 21291392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophore modeling and parallel screening for PPAR ligands.
    Markt P; Schuster D; Kirchmair J; Laggner C; Langer T
    J Comput Aided Mol Des; 2007; 21(10-11):575-90. PubMed ID: 17960326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
    Feldman PL; Lambert MH; Henke BR
    Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA; Sylte I
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands.
    Subramani PA; Reddy MC; Narala VR
    Endocr Metab Immune Disord Drug Targets; 2013 Jun; 13(2):175-83. PubMed ID: 23713695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar.
    Liu XY; Wang RL; Xu WR; Tang LD; Wang SQ; Chou KC
    Protein Pept Lett; 2011 Oct; 18(10):1021-7. PubMed ID: 21592078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism.
    Lamas Bervejillo M; Ferreira AM
    Adv Exp Med Biol; 2019; 1127():39-57. PubMed ID: 31140170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.
    Bernardes A; Souza PC; Muniz JR; Ricci CG; Ayers SD; Parekh NM; Godoy AS; Trivella DB; Reinach P; Webb P; Skaf MS; Polikarpov I
    J Mol Biol; 2013 Aug; 425(16):2878-93. PubMed ID: 23707408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors.
    Degenhardt T; Matilainen M; Herzig KH; Dunlop TW; Carlberg C
    J Biol Chem; 2006 Dec; 281(51):39607-19. PubMed ID: 17062566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
    Hong F; Xu P; Zhai Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for iloprost as a dual peroxisome proliferator-activated receptor alpha/delta agonist.
    Jin L; Lin S; Rong H; Zheng S; Jin S; Wang R; Li Y
    J Biol Chem; 2011 Sep; 286(36):31473-9. PubMed ID: 21775429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure.
    Jacobs MN; Dickins M; Lewis DF
    J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):117-32. PubMed ID: 12710995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
    Naumann T; Matter H
    J Med Chem; 2002 Jun; 45(12):2366-78. PubMed ID: 12036347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.
    Wu CC; Baiga TJ; Downes M; La Clair JJ; Atkins AR; Richard SB; Fan W; Stockley-Noel TA; Bowman ME; Noel JP; Evans RM
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2563-E2570. PubMed ID: 28320959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.